Emergent BioSolutions Inc.
EBS
$4.54
-$0.08-1.73%
NYSE
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 36.77% | 143.58% | -8.30% | 104.83% | 26.12% |
| Total Depreciation and Amortization | -12.16% | -5.71% | -13.37% | -19.36% | 28.70% |
| Total Amortization of Deferred Charges | -61.40% | -217.54% | -43.82% | 590.00% | 470.00% |
| Total Other Non-Cash Items | 142.86% | -120.72% | -63.23% | -429.63% | 111.90% |
| Change in Net Operating Assets | -299.30% | -0.30% | 244.19% | -170.08% | -74.09% |
| Cash from Operations | -348.91% | 156.17% | 141.52% | 65.98% | -65.41% |
| Capital Expenditure | 85.09% | 53.97% | 63.20% | 28.48% | 51.69% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | 100.00% |
| Cash from Investing | 350.88% | 692.59% | -101.79% | 28.48% | 74.89% |
| Total Debt Issued | -100.00% | -- | -- | -- | -94.44% |
| Total Debt Repaid | 100.00% | -862.70% | 87.81% | -5.95% | -87.06% |
| Issuance of Common Stock | 14.29% | -- | -92.63% | -- | -65.00% |
| Repurchase of Common Stock | -200.00% | -200.00% | 0.00% | 80.95% | 75.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -89.36% | -319.30% | 89.55% | 487.62% | -98.67% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -236.36% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -312.55% | 10,775.00% | 97.66% | 84.60% | -94.05% |